CC
PCRX icon

Centiva Capital’s Pacira BioSciences PCRX Stock Holding History

Centiva Capital’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-26,473
Closed -$398K – 2224
2024
Q3 		$398K Buy
+26,473
New +$453K 0.01% 1407
2023
Q1 		– Sell
-6,512
Closed -$251K – 1757
2022
Q4 		$251K Buy
+6,512
New +$317K 0.01% 1025
2021
Q4 		– Sell
-7,461
Closed -$417K – 1462
2021
Q3 		$417K Buy
+7,461
New +$430K 0.03% 684

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Centiva Capital's PCRX Position: Q4 2024 in Review

Centiva Capital sold out of Pacira BioSciences (PCRX) in Q4 2024, closing a stake of 26,473 shares — an estimated $398K sold.

Centiva Capital first reported a position in PCRX in Q3 2021 and held it in 3 quarters. The position peaked at $417K in Q3 2021. 233 funds tracked by Wall St. Rank hold PCRX as of Q4 2024.

  • Centiva Capital reported no remaining Pacira BioSciences position as of Q4 2024 after selling out during the quarter.
  • Centiva Capital sold 26,473 Pacira BioSciences shares in Q4 2024, an estimated $398K.
  • Centiva Capital first reported a position in Pacira BioSciences in Q3 2021 and held it in 3 quarters.
  • Centiva Capital's Pacira BioSciences position peaked at $417K in Q3 2021.
  • 233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2024.

Based on Centiva Capital's 13F filing for Q4 2024, filed 14 Feb 2025.